Dummer, Reinhard <br/><br/>
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF  [electronic resource] 

 -  The Lancet. Oncology  03 2020 
 - 358-372 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(20)30062-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Double-Blind Method<br/>Drug Resistance, Neoplasm--drug effects<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Imidazoles--administration & dosage<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Mutation<br/>Neoplasm Metastasis<br/>Neoplasm Recurrence, Local--drug therapy<br/>Oximes--administration & dosage<br/>Prognosis<br/>Proto-Oncogene Proteins B-raf--genetics<br/>Pyridones--administration & dosage<br/>Pyrimidinones--administration & dosage<br/>Salvage Therapy<br/>Skin Neoplasms--drug therapy<br/>Survival Rate<br/>Young Adult